Asia Pacific Point Of Care Poc Drug Abusepoint Of Care Poc Drug Abuse Testing Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2024 –2031 |
 Market Size (Base Year) |
USD 283.30 Million |
 Market Size (Forecast Year) |
USD 438.29 Million |
 CAGR |
% |
| Major Markets Players |
Asia-Pacific Point-of-Care (POC) Drug Abuse Testing Market, By Drug Type (Amphetamines, Opiates, Cannabinoids, Cocaine, Barbiturates, Benzodiazepines, Methadone, Phencyclidine, Tricyclic Antidepressants, and Others), Products (Devices and Consumables and Accessories), Prescription (Over the Counter Testing and Prescription-Based Testing), Sample Type (Urine, Saliva, Blood, Hair, Breath, and Others), Testing Type (Random Testing, Post-Incident Testing, and Abstinence Testing), Application (Medical Screening, Workplace Screening, Law Enforcement and Criminal Justice, Pain Management, Substance Abuse Treatment and Rehabilitation, Parental or Home Drug Testing, Sports and Athletics Testing, Drug Screening in Schools and Educational Institutions, and Others), End User (Healthcare Facilities, Employers, Government Institutes, and Others), Distribution Channel (Direct Tender, Retails Sales, and Others) - Industry Trends and Forecast to 2031.
Asia-Pacific Point-of-Care (POC) Drug Abuse Testing Market Analysis and Size
The market is driven by increasing awareness and emphasis on drug abuse prevention and management, along with the growing need for quick and accurate drug testing in diverse environments. Key factors fueling market growth include rising drug abuse rates, stringent regulatory requirements for drug testing in workplaces, and advancements in POC testing technologies that offer enhanced accuracy and user convenience. Additionally, the growing prevalence of substance abuse disorders across different demographics contributes to the demand for effective and accessible drug testing solutions.
The Asia-Pacific Point-of-Care (POC) drug abuse testing market encompasses a range of diagnostic technologies and solutions designed to detect the presence of illicit substances or controlled drugs in an individual’s system at the location of care, rather than in a traditional laboratory setting. These tests provide rapid, on-the-spot results, which are crucial for timely decision-making and intervention in various settings such as medical facilities, emergency rooms, workplaces, and even in home settings. The market includes devices and testing kits for detecting drugs in urine, saliva, blood, and other biological samples.
Data Bridge Market Research analyzes that the Asia-Pacific Point-of-Care (POC) drug abuse testing market is expected to reach USD 438.29 million by 2031 from USD 283.30 million in 2023, growing with a CAGR of 5.8% in the forecast period of 2024 to 2031.
|
Report Metric |
Details |
|
Forecast Period |
2024 to 2031 |
|
Base Year |
2023 |
|
Historic Years |
2022 (Customizable 2016-2021) |
|
Quantitative Units |
Revenue in USD Million |
|
Segments Covered |
Drug Type (Amphetamines, Opiates, Cannabinoids, Cocaine, Barbiturates, Benzodiazepines, Methadone, Phencyclidine, Tricyclic Antidepressants, and Others), Products (Devices and Consumables and Accessories), Prescription (Over the Counter Testing and Prescription-Based Testing), Sample Type (Urine, Saliva, Blood, Hair, Breath, and Others), Testing Type (Random Testing, Post-Incident Testing, and Abstinence Testing), Application (Medical Screening, Workplace Screening, Law Enforcement and Criminal Justice, Pain Management, Substance Abuse Treatment and Rehabilitation, Parental or Home Drug Testing, Sports and Athletics Testing, Drug Screening in Schools and Educational Institutions, and Others), End User (Healthcare Facilities, Employers, Government Institutes, and Others), Distribution Channel (Direct Tender, Retails Sales, and Others) |
|
Countries Covered |
China, India, Japan, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, and Rest of Asia-Pacific |
|
Market Players Covered |
Abbott Laboratories, Quest Diagnostics Incorporated, Thermo Fisher Scientific, Inc., F.Hoffman-La Roche Ltd., Siemens Healthineers AG, MP Biomedicals., Beijing Hotgen Biotechn Co., LTD., Assure Tech (Hangzhou) co., ltd., Accubio Tech Co., ltd. Premier biotech,inc., Wondfo and, among others |
Market Definition
Point-of-Care (PoC) drug abuse testing refers to rapid screening methods used to detect the presence of drugs or their metabolites in a person's system at the site of care, such as clinics or emergency rooms. These tests provide quick results, enabling timely decision-making for treatment or intervention. Typically involving urine, saliva, or blood samples, PoC testing is essential for monitoring substance use, ensuring patient safety, and facilitating access to appropriate support services.
Asia-Pacific Point-of-Care (POC) Drug Abuse Testing Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail as below:
Drivers
- Rising Incidence of Drug Abuse
Drug abuse involving opiates, cannabinoids, and amphetamines has been growing regionally, creating a public health crisis that requires immediate and scalable solutions. Healthcare providers, law enforcement agencies, and employers are increasingly relying on POC drug testing as it offers rapid, accurate, and on-site detection, which is critical in managing the consequences of drug abuse.
In healthcare, the need for quick detection of drug abuse is essential to offer timely interventions, especially in emergency cases or rehabilitation centers. In law enforcement, the ability to test individuals on-site accelerates decision-making and enhances efforts to curb drug-related crimes. Similarly, workplaces are adopting POC drug testing to maintain a drug-free environment, reduce liability, and comply with safety regulations.
Technological advancements in POC testing devices further support the growing demand for rapid, reliable testing methods. These devices are becoming more portable, user-friendly, and capable of detecting a wide range of substances, making them ideal for use in non-laboratory settings.
For Instance,
- In January 2024, according to an article published by NCBI, Opioid Use Disorder (OUD) affects over 16 million people worldwide, including 2.1 million in the U.S., leading to more than 120,000 deaths regionally each year. The prevalence of opioid use and dependency is high, with up to 50% of long-term opioid users meeting OUD criteria. The rising incidence of opioid-related issues drives the need for effective drug testing solutions, thereby fuelling growth in the Asia-Pacific Point-of-Care (POC) drug abuse testing market
- In August 2023, according to an article published by WHO, in 2019, approximately 600,000 deaths regionally were linked to drug use, with about 80% related to opioids. Of these, around 125,000 were due to opioid overdose, while non-fatal overdoses are significantly more common. The rise in opioid overdoses is attributed to increased opioid availability for chronic pain management and the presence of potent opioids on the illicit market. In the USA, drug overdose deaths totaled 70,630 in 2019, with synthetic opioids involved in about half of these cases.
Growth in Home and Parental Drug Testing Kits
The growing demand for easy-to-use, over-the-counter drug testing kits for home use reflects a strong consumer preference for privacy and convenience in monitoring substance use. Parents are increasingly adopting these kits to detect and prevent substance abuse among teenagers, while individuals are opting for self-testing options for personal reasons.
Technological advancements have led to the creation of more accurate, reliable, and user-friendly drug testing products, enabling consumers to perform tests privately at home without professional assistance. This convenience reduces the stigma associated with drug testing, fostering wider adoption of these solutions. Home testing kits are now more sensitive and capable of detecting a broad range of drugs, providing results that are comparable to those from laboratory tests.
Increased awareness of substance abuse and the easy availability of these kits through pharmacies and online platforms are contributing to market growth. The trend is further supported by a growing preference for non-invasive sample collection methods, such as saliva or urine tests, which are simple to use at home.
For instance,
- In November 2023, according to an article published by DNA Forensics Laboratory Pvt. Ltd., in recent years, at-home drug testing kits have become increasingly popular due to their convenience and ease of access. These kits enable individuals to conduct drug tests privately at home, typically including test strips or collection devices along with clear instructions for sample collection and result interpretation. This trend towards home testing highlights the "growth in home and parental drug testing kits" and drives the demand for such products. The growing preference for private and convenient drug testing solutions propels the expansion of the Asia-Pacific Point-of-Care (POC) drug abuse testing market.
In conclusion, the rising demand for home and parental drug testing kits is driving significant growth in the POC drug abuse testing market by offering consumers private, convenient, and reliable options for substance abuse monitoring, fueling expansion in this segment.
Opportunity
- Growing Awareness and the Campaign for Drug Testing
The increasing awareness surrounding the dangers of drug abuse, coupled with robust public health campaigns and government support, presents a significant opportunity for growth in the Asia-Pacific Point-of-Care (POC) drug abuse testing market. As society becomes more cognizant of the detrimental impacts of substance abuse, there is a growing demand for accessible and effective testing solutions. Public health campaigns, often spearheaded by governmental and non-governmental organizations, play a crucial role in educating communities about the importance of early detection and intervention. These initiatives not only amplify the visibility of drug abuse issues but also advocate for the use of point-of-care testing as a preventive measure. Furthermore, government support through funding and policy-making enhances the accessibility of POC drug testing solutions by promoting regulatory frameworks that facilitate the adoption of these technologies in various settings, including workplaces, schools, and public health programs. The combination of heightened awareness and strategic support fosters an environment conducive to market expansion, driving innovation and increasing the availability of advanced testing solutions to address the evolving needs of society.
- In December 2023, according to the article published by the Greater London Authority, UK government allocated USD 1.54 million to this mission, focusing on testing for 14 different drugs with the rising awareness and proactive government initiatives in the UK have led to the implementation of random mandatory drug testing for individuals released from prison, aiming to reduce crime rates. This move underscores the nation's commitment to tackling substance abuse and its impact on criminal behavior, reflecting broader efforts to enhance public safety and well-being.
- In July 2021, according to the article published by Commonwealth of Australia and the Department of Health and Aged Care, the Australian government launched the National Ice Action Strategy, which included significant investments to enhance Point-of-Care (POC) drug abuse testing. This initiative aimed to curb the growing use of methamphetamines, commonly known as "ice," by providing law enforcement and healthcare providers with more accessible and accurate drug testing tools. The strategy also focused on expanding the availability of POC testing in remote and rural areas, ensuring that communities across the country could benefit from timely and effective drug detection and intervention measures.
Hence, the convergence of growing awareness, active public health campaigns, and strong government support is poised to significantly benefit the Asia-Pacific Point-of-Care (POC) drug abuse testing market. This dynamic environment not only promotes the adoption of drug testing technologies but also encourages the development of more sophisticated and accessible solutions. As these factors continue, the future of POC drug abuse testing looks promising, with enhanced opportunities for innovation, broader market reach, and improved public health outcomes.
Restraint/Challenge
- High Costs Associated with the Testing
The complexity of developing reliable and accurate POC drug abuse tests often requires advanced technology, specialized materials, and rigorous validation processes, all of which contribute to elevated production costs. These costs are further compounded by stringent regulatory requirements, as ensuring compliance with international standards demands extensive testing, quality control, and documentation, adding to the overall expense. Additionally, the need for consistent research and development to keep pace with emerging drug abuse patterns and to enhance the sensitivity and specificity of these tests drives up the costs even more. For healthcare providers, the high upfront investment required to integrate these testing solutions into their practices can be prohibitive, particularly for smaller clinics or organizations with limited budgets. This financial burden can deter the adoption of POC drug abuse testing despite its potential benefits in terms of speed and convenience. The situation is exacerbated in low- and middle-income countries, where healthcare budgets are already strained, and the added cost of POC testing can be a barrier to implementation, limiting the market's expansion into these regions. Moreover, the high cost can lead to disparities in healthcare access, as only well-funded institutions may be able to afford these advanced testing methods, leaving vulnerable populations without adequate testing and care. This challenge is not only a financial one but also an ethical issue, as the inability to provide affordable testing solutions undermines the efforts to combat drug abuse on a broader scale.
For instance,
- In May 2023, according to an article published by the National Library of Medicine, POC testing was costlier performed on an individual basis when compared to traditional laboratory testing due to the single-use nature of most POCT devices, which adds to the overall expenses.
- In January 2024, according to an article published by Checkr., the cost of drug testing for comprehensive laboratory panels can exceed USD 500. Onsite tests typically range from USD 20 to USD 40, but the need for lab confirmation can drive prices up, starting at USD 50 and varying based on the test type and substances screened. High volumes of tests might reduce the average cost per test, but the overall expense can still be substantial.
Hence, the high cost of POC drug abuse testing creates significant barriers to its broader adoption, limiting accessibility, especially in resource-constrained regions. This financial challenge not only hampers market growth but also exacerbates healthcare inequalities, preventing many from receiving timely and effective drug abuse testing, and is expected to act as a challenge for market growth in the future.
Recent Developments
- In August 2024, Abbott announced a Asia-Pacific partnership with Medtronic on August 7, 2024, to integrate Abbott's advanced FreeStyle Libre Continuous Glucose Monitoring (CGM) technology with Medtronic's insulin delivery systems. This collaboration aimed to enable automatic insulin adjustments and improve diabetes management, benefiting over 11 million people worldwide. Financial terms were undisclosed
- In March 2024, Abbott extended its partnership with Real Madrid and the Real Madrid Foundation through the 2026-2027 season, continuing as their Asia-Pacific health sciences and nutrition partner. Since 2021, Abbott provided over 25,000 hours of nutrition education and screened more than 3,000 children for malnutrition
- In August 2023, SSM Health, Siemens Healthineers partner to advance health equity and empower workforce development in underserved communities. The partnership with SSM Health benefits Siemens Healthineers by expanding its market presence, increasing visibility of its technology, fostering long-term growth, and enhancing its reputation in the healthcare sector
- In February 2024, Roche entered into collaboration agreement with PathAI to expand digital pathology capabilities for companion diagnostics. The collaboration provides Roche with PathAI’s advanced AI technology for improving companion diagnostics. It ensures exclusive, tailored solutions and accelerates algorithm development while allowing Roche to continue developing its own diagnostics
- In November 2023, Roche launched next-generation qPCR system to advance clinical needs in molecular diagnostics and address public health challenges. Roche’s next-generation qPCR system boosts its market position, meets clinical and public health needs, and opens new revenue opportunities while showcasing its commitment to innovation
Asia-Pacific Point-of-Care (POC) Drug Abuse Testing Market Scope
The Asia-Pacific Point-of-Care (POC) drug abuse testing market is segmented into eight notable segments based on drug type, products, prescription, sample type, testing type, application, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Drug Type
- Amphetamines
- Opiates
- Cannabinoids
- Cocaine
- Barbiturates
- Benzodiazepines
- Methadone
- Phencyclidine
- Tricyclic Antidepressants
- Others
On the basis of drug type, the market is segmented into amphetamines, cannabinoids, opiates, cocaine, benzodiazepines, barbiturates, phencyclidine, methadone, tricyclic antidepressants, and others.
Products
- Devices
- Consumables and Accessories
On the basis of products, the market is segmented into devices and consumables and accessories.
Prescription
- Over the Counter Testing
- Prescription-Based Testing
On the basis of prescription mode, the market is segmented into prescription-based testing, and over the counter testing.
Sample Type
- Urine
- Saliva
- Blood
- Hair
- Breath
- Others
On the basis of sample type, the market is segmented into urine, saliva, blood, hair, breath, and others.
Testing Type
- Random Testing
- Post-Incident Testing
- Abstinence Testing
On the basis of testing type, the market is segmented into random testing, post-incident testing, and abstinence testing.
Application
- Medical Screening
- Workplace Screening
- Law Enforcement and Criminal Justice
- Pain Management
- Substance Abuse Treatment and Rehabilitation
- Parental or Home Drug Testing
- Sports and Athletics Testing
- Drug Screening in Schools and Educational Institutions
- Others
On the basis of application, the market is segmented medical screening, workplace screening, law enforcement and criminal justice, pain management, substance abuse treatment and rehabilitation, parental or home drug testing, sports and athletics testing, drug screening in schools and educational institutions, and others.
End User
- Healthcare Facilities
- Employers
- Government Institutes
- Others
On the basis of end user, the market is segmented into healthcare facilities, employers, government institute, and others.
Distribution Channel
- Direct Tender
- Retail Sales
- Others
On the basis of distribution channel, the market is segmented into direct tender, retails sales, and others.
Asia-Pacific Point-of-Care (POC) Drug Abuse Testing Market Regional Analysis/Insights
Asia-Pacific Point-of-Care (POC) drug abuse testing market is analyzed, and market size insights and trends are provided by based on drug type, products, prescription, sample type, testing type, application, end user, distribution channel as referenced above.
The countries covered in this market report are China, India, Japan, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, and rest of Asia-Pacific.
China is expected to dominate in the Asia-Pacific market due to its large population, increasing healthcare spending, expanding pharmaceutical industry, growing consumer awareness.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of regional brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Asia-Pacific Point-of-Care (POC) Drug Abuse Testing Market Share Analysis
The Asia-Pacific Point-of-Care (POC) drug abuse testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, regional presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the Asia-Pacific Point-of-Care (POC) drug abuse testing market.
Some of the major players operating in the Asia-Pacific Point-of-Care (POC) drug abuse testing market are Abbott Laboratories, Quest Diagnostics Incorporated, Thermo Fisher Scientific, Inc., F.Hoffman-La Roche Ltd., Siemens Healthineers AG, MP Biomedicals., Beijing Hotgen Biotechn Co., LTD., Assure Tech (Hangzhou) co., ltd., Accubio Tech Co., ltd. Premier biotech,inc., and Wondfo, among others.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTERS FIVE FORCES ANALYSIS
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISING INCIDENCE OF DRUG ABUSE
5.1.2 GROWING EMPHASIS ON WORKPLACE SAFETY
5.1.3 GROWTH IN HOME AND PARENTAL DRUG TESTING KITS
5.1.4 RISING USE OF POC TESTING IN HEALTHCARE FACILITIES
5.2 RESTRAINTS
5.2.1 DATA SECURITY AND PRIVACY CONCERNS
5.2.2 LACK OF ACCURACY AND TECHNICAL CHALLENGES
5.3 OPPORTUNITIES
5.3.1 GROWING AWARENESS AND THE CAMPAIGN FOR DRUG TESTING
5.3.2 STRATEGIC INITIATION AND DECISION TAKEN BY THE MARKET PLAYERS
5.3.3 EXPANDING PRODUCT RANGE FOR POINT-OF-CARE DRUG ABUSE TESTING
5.4 CHALLENGES
5.4.1 LIMITED AWARENESS AND ACCEPTANCE
5.4.2 HIGH COSTS ASSOCIATED WITH THE TESTING
6 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE
6.1 OVERVIEW
6.2 AMPHETAMINES
6.3 OPIATES
6.4 CANNABINOIDS
6.5 COCAINE
6.6 BARBITURATES
6.7 BENZODIAZEPINES
6.8 METHADONE
6.9 PHENCYCLIDINE
6.1 TRICYCLIC ANTIDEPRESSANTS
6.11 OTHERS
7 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS
7.1 OVERVIEW
7.2 DEVICES
7.2.1 ANALYZER
7.2.1.1 IMMUNOASSAY ANALYZER
7.2.1.1.1 HIGH VOLUME
7.2.1.1.2 MID VOLUME
7.2.1.1.3 LOW VOLUME
7.2.1.2 BREATHALYZER
7.2.1.2.1 ELECTROCHEMICAL FUEL CELL BREATH ANALYZERS
7.2.1.2.2 INFRARED OPTICAL SENSOR BREATH ANALYZERS
7.2.1.2.3 SEMICONDUCTOR BREATH ANALYZERS
7.2.2 RAPID DEVICES
7.2.3 DRUG TESTING CASSETTE
7.2.4 DRUG TESTING CUPS
7.2.5 DIP CARDS/STRIPS
7.2.6 ORAL FLUID TESTING DEVICES
7.2.7 OTHERS
7.2.8 MODALITY
7.2.9 HANDHELD
7.2.10 MOBILE
7.2.11 MANUAL
7.2.12 AUTOMATED
7.3 CONSUMABLES AND ACCESSORIES
7.3.1 ASSAY KITS AND REAGENTS
7.3.2 PROBES
7.3.3 OTHERS
7.3.3.1 DAST-10
7.3.3.2 Plasma Protein Binding
7.3.3.3 Plasma and Serum Stability
7.3.3.4 Others
7.3.3.4.1 Multi-Panel Drug Test Kits
7.3.3.4.2 Single-Panel Drug Test Kits
8 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION
8.1 OVERVIEW
8.2 OVER THE COUNTER TESTING
8.3 PRESCRIPTION-BASED TESTING
9 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE
9.1 OVERVIEW
9.2 URINE
9.3 SALIVA
9.4 BLOOD
9.5 HAIR
9.6 BREATH
9.7 OTHERS
10 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE
10.1 OVERVIEW
10.2 RANDOM TESTING
10.3 POST-INCIDENT TESTING
10.4 ABSTINENCE TESTING
11 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 MEDICAL SCREENING
11.3 WORKPLACE SCREENING
11.4 LAW ENFORCEMENT AND CRIMINAL JUSTICE
11.5 PAIN MANAGEMENT
11.6 SUBSTANCE ABUSE TREATMENT AND REHABILITATION
11.7 PARENTAL OR HOME DRUG TESTING
11.8 SPORTS AND ATHLETICS TESTING
11.9 DRUG SCREENING IN SCHOOLS AND EDUCATIONAL INSTITUTIONS
11.1 OTHERS
12 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER
12.1 OVERVIEW
12.2 HEALTHCARE FACILITIES
12.2.1 HOSPITALS
12.2.2 EMERGENCY DEPARTMENT
12.2.3 CENTRAL LABS
12.2.4 CLINICS
12.2.5 POISON CONTROL CENTERS
12.2.6 OTHERS
12.3 EMPLOYERS
12.4 GOVERNMENT INSTITUTES
12.5 OTHERS
13 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
13.4 OTHERS
14 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION
14.1 ASIA-PACIFIC
14.1.1 CHINA
14.1.2 INDIA
14.1.3 JAPAN
14.1.4 SOUTH KOREA
14.1.5 AUSTRALIA
14.1.6 SINGAPORE
14.1.7 MALAYSIA
14.1.8 THAILAND
14.1.9 INDONESIA
14.1.10 PHILIPPINES
14.1.11 VIETNAM
14.1.12 REST OF ASIA-PACIFIC
15 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
16 SWOT ANALYSIS
17 COMPANY PROFILES
17.1 ABBOTT LABORATORIES
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 SIEMENS HEALTHINEERS AG
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENTS
17.3 QUEST DIAGNOSTICS INCORPORATED
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.4 THERMO FISHER SCIENTIFIC INC.
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 F.HOFFMAN-LA ROCHE LTD.
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT UPDATES
17.5.6 RECENT UPDATES
17.6 ACCUBIOTECH CO., LTD.
17.6.1 COMPANY SNAPSHOT
17.6.2 PRODUCT PORTFOLIO
17.6.3 RECENT DEVELOPMENT
17.7 ADVACARE PHARMA
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT UPDATES
17.8 AGILENT TECHNOLOGIES, INC
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT UPDATES
17.9 ASSURE TECH (HANGZHOU) CO., LTD.
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.1 BD
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENT
17.11 BEIJING HOTGEN BIOTECHN CO., LTD.
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 RECENT DEVELOPMENT
17.12 BIOEASY BIOTECHNOLOGY CO., LTD.,
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENT
17.13 BIO-RAD LABORATORIES, INC.
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENT
17.14 CLIAWAIVED, INC.
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENT
17.15 DRUGSCAN
17.15.1 COMPANY SNAPSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENT
17.16 EGENS GROUP (NANTONG YISHI BIOTECHNOLOGY CO., LTD.)
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENT
17.17 HANGZHOU ALLTEST BIOTECH CO.,LTD
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENT
17.18 JOYSBIO (TIANJIN) BIOTECHNOLOGY CO., LTD
17.18.1 COMPANY SNAPSHOT
17.18.2 PRODUCT PORTFOLIO
17.18.3 RECENT UPDATES
17.19 LIFESIGN LLC.
17.19.1 COMPANY SNAPSHOT
17.19.2 PRODUCT PORTFOLIO
17.19.3 RECENT DEVELOPMENT
17.2 MERCK KGAA
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PRODUCT PORTFOLIO
17.20.4 RECENT DEVELOPMENTS
17.21 MP BIOMEDICALS
17.21.1 COMPANY SNAPSHOT
17.21.2 PRODUCT PORTFOLIO
17.21.3 RECENT DEVELOPMENT
17.22 PREMIER BIOTECH, INC.
17.22.1 COMPANY SNAPSHOT
17.22.2 PRODUCT PORTFOLIO
17.22.3 RECENT DEVELOPMENT
17.23 SYSMEX CORPORATION
17.23.1 COMPANY SNAPSHOT
17.23.2 REVENUE ANALYSIS
17.23.3 PRODUCT PORTFOLIO
17.23.4 RECENT DEVELOPMENTS
17.24 WONDFO
17.24.1 COMPANY SNAPSHOT
17.24.2 PRODUCT PORTFOLIO
17.24.3 RECENT DEVELOPMENT
17.25 XIAMEN BOSON BIOTECH CO., LTD.
17.25.1 COMPANY SNAPSHOT
17.25.2 PRODUCT PORTFOLIO
17.25.3 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
表格列表
TABLE 1 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 2 ASIA-PACIFIC AMPHETAMINES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 3 ASIA-PACIFIC OPIATES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 4 ASIA-PACIFIC CANNABINOIDS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 5 ASIA-PACIFIC COCAINE IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 6 ASIA-PACIFIC BARBITURATES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 7 ASIA-PACIFIC BENZODIAZEPINES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 8 ASIA-PACIFIC METHADONE IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 9 ASIA-PACIFIC PHENCYCLIDINE IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 10 ASIA-PACIFIC TRICYCLIC ANTIDEPRESSANTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 11 ASIA-PACIFIC OTHERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 12 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 13 ASIA-PACIFIC DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 14 ASIA-PACIFIC DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 15 ASIA-PACIFIC DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 16 ASIA-PACIFIC ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 17 ASIA-PACIFIC IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 18 ASIA-PACIFIC BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 19 ASIA-PACIFIC BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 20 ASIA-PACIFIC DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 21 ASIA-PACIFIC DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 22 ASIA-PACIFIC CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 23 ASIA-PACIFIC CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 24 ASIA-PACIFIC ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 25 ASIA-PACIFIC ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 26 ASIA-PACIFIC ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 27 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 28 ASIA-PACIFIC OVER THE COUNTER TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 29 ASIA-PACIFIC PRESCRIPTION-BASED TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 30 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 31 ASIA-PACIFIC URINE IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 32 ASIA-PACIFIC SALIVA IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 33 ASIA-PACIFIC BLOOD IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 34 ASIA-PACIFIC HAIR IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 35 ASIA-PACIFIC BREATH IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 36 ASIA-PACIFIC OTHERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 37 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 38 ASIA-PACIFIC RANDOM TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 39 ASIA-PACIFIC POST-INCIDENT TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 40 ASIA-PACIFIC ABSTINENCE TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 41 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 42 ASIA-PACIFIC MEDICAL SCREENING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 43 ASIA-PACIFIC WORKPLACE SCREENING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 44 ASIA-PACIFIC LAW ENFORCEMENT AND CRIMINAL JUSTICE IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 45 ASIA-PACIFIC PAIN MANAGEMENT IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 46 ASIA-PACIFIC SUBSTANCE ABUSE TREATMENT AND REHABILITATION IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 47 ASIA-PACIFIC PARENTAL OR HOME DRUG TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 48 ASIA-PACIFIC SPORTS AND ATHLETICS TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 49 ASIA-PACIFIC DRUG SCREENING IN SCHOOLS AND EDUCATIONAL INSTITUTIONS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 50 ASIA-PACIFIC OTHERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 51 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 52 ASIA-PACIFIC HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 53 ASIA-PACIFIC HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 54 ASIA-PACIFIC EMPLOYERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 55 ASIA-PACIFIC GOVERNMENT INSTITUTES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 56 ASIA-PACIFIC OTHERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 57 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 58 ASIA-PACIFIC DIRECT TENDER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 59 ASIA-PACIFIC RETAIL SALES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 60 ASIA-PACIFIC OTHERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 61 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 62 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 63 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 64 ASIA-PACIFIC DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 65 ASIA-PACIFIC DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 66 ASIA-PACIFIC DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 67 ASIA-PACIFIC ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 68 ASIA-PACIFIC IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 69 ASIA-PACIFIC BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 70 ASIA-PACIFIC BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 71 ASIA-PACIFIC BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 72 ASIA-PACIFIC DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 73 ASIA-PACIFIC DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 74 ASIA-PACIFIC CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 75 ASIA-PACIFIC ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 76 ASIA-PACIFIC ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 77 ASIA-PACIFIC ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 78 ASIA-PACIFIC ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 79 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 80 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 81 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 82 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 83 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 84 ASIA-PACIFIC HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 85 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 86 CHINA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 87 CHINA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 88 CHINA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 89 CHINA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 90 CHINA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 91 CHINA ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 92 CHINA IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 93 CHINA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 94 CHINA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 95 CHINA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 96 CHINA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 97 CHINA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 98 CHINA CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 99 CHINA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 100 CHINA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 101 CHINA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 102 CHINA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 103 CHINA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 104 CHINA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 105 CHINA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 106 CHINA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 107 CHINA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 108 CHINA HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 109 CHINA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 110 INDIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 111 INDIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 112 INDIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 113 INDIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 114 INDIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 115 INDIA ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 116 INDIA IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 117 INDIA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 118 INDIA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 119 INDIA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 120 INDIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 121 INDIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 122 INDIA CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 123 INDIA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 124 INDIA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 125 INDIA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 126 INDIA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 127 INDIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 128 INDIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 129 INDIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 130 INDIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 131 INDIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 132 INDIA HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 133 INDIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 134 JAPAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 135 JAPAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 136 JAPAN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 137 JAPAN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 138 JAPAN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 139 JAPAN ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 140 JAPAN IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 141 JAPAN BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 142 JAPAN BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 143 JAPAN BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 144 JAPAN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 145 JAPAN DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 146 JAPAN CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 147 JAPAN ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 148 JAPAN ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 149 JAPAN ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 150 JAPAN ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 151 JAPAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 152 JAPAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 153 JAPAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 154 JAPAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 155 JAPAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 156 JAPAN HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 157 JAPAN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 158 SOUTH KOREA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 159 SOUTH KOREA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 160 SOUTH KOREA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 161 SOUTH KOREA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 162 SOUTH KOREA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 163 SOUTH KOREA ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 164 SOUTH KOREA IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 165 SOUTH KOREA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 166 SOUTH KOREA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 167 SOUTH KOREA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 168 SOUTH KOREA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 169 SOUTH KOREA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 170 SOUTH KOREA CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 171 SOUTH KOREA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 172 SOUTH KOREA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 173 SOUTH KOREA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 174 SOUTH KOREA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 175 SOUTH KOREA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 176 SOUTH KOREA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 177 SOUTH KOREA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 178 SOUTH KOREA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 179 SOUTH KOREA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 180 SOUTH KOREA HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 181 SOUTH KOREA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 182 AUSTRALIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 183 AUSTRALIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 184 AUSTRALIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 185 AUSTRALIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 186 AUSTRALIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 187 AUSTRALIA ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 188 AUSTRALIA IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 189 AUSTRALIA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 190 AUSTRALIA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 191 AUSTRALIA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 192 AUSTRALIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 193 AUSTRALIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 194 AUSTRALIA CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 195 AUSTRALIA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 196 AUSTRALIA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 197 AUSTRALIA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 198 AUSTRALIA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 199 AUSTRALIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 200 AUSTRALIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 201 AUSTRALIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 202 AUSTRALIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 203 AUSTRALIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 204 AUSTRALIA HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 205 AUSTRALIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 206 SINGAPORE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 207 SINGAPORE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 208 SINGAPORE DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 209 SINGAPORE DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 210 SINGAPORE DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 211 SINGAPORE ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 212 SINGAPORE IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 213 SINGAPORE BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 214 SINGAPORE BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 215 SINGAPORE BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 216 SINGAPORE DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 217 SINGAPORE DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 218 SINGAPORE CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 219 SINGAPORE ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 220 SINGAPORE ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 221 SINGAPORE ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 222 SINGAPORE ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 223 SINGAPORE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 224 SINGAPORE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 225 SINGAPORE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 226 SINGAPORE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 227 SINGAPORE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 228 SINGAPORE HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 229 SINGAPORE POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 230 MALAYSIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 231 MALAYSIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 232 MALAYSIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 233 MALAYSIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 234 MALAYSIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 235 MALAYSIA ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 236 MALAYSIA IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 237 MALAYSIA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 238 MALAYSIA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 239 MALAYSIA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 240 MALAYSIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 241 MALAYSIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 242 MALAYSIA CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 243 MALAYSIA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 244 MALAYSIA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 245 MALAYSIA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 246 MALAYSIA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 247 MALAYSIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 248 MALAYSIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 249 MALAYSIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 250 MALAYSIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 251 MALAYSIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 252 MALAYSIA HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 253 MALAYSIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 254 THAILAND POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 255 THAILAND POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 256 THAILAND DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 257 THAILAND DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 258 THAILAND DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 259 THAILAND ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 260 THAILAND IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 261 THAILAND BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 262 THAILAND BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 263 THAILAND BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 264 THAILAND DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 265 THAILAND DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 266 THAILAND CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 267 THAILAND ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 268 THAILAND ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 269 THAILAND ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 270 THAILAND ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 271 THAILAND POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 272 THAILAND POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 273 THAILAND POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 274 THAILAND POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 275 THAILAND POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 276 THAILAND HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 277 THAILAND POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 278 INDONESIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 279 INDONESIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 280 INDONESIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 281 PHILIPPINES DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 282 PHILIPPINES DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 283 INDONESIA ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 284 INDONESIA IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 285 INDONESIA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 286 PHILIPPINES BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 287 PHILIPPINES BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 288 INDONESIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 289 INDONESIA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 290 INDONESIA CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 291 INDONESIA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 292 PHILIPPINES ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 293 PHILIPPINES ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 294 INDONESIA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 295 INDONESIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 296 INDONESIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 297 INDONESIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 298 INDONESIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 299 INDONESIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 300 INDONESIA HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 301 INDONESIA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 302 PHILIPPINES POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 303 PHILIPPINES POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 304 PHILIPPINES DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 305 PHILIPPINES DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 306 PHILIPPINES DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 307 PHILIPPINES ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 308 PHILIPPINES IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 309 PHILIPPINES BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 310 PHILIPPINES BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 311 PHILIPPINES BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 312 PHILIPPINES DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 313 PHILIPPINES DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 314 PHILIPPINES CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 315 PHILIPPINES ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 316 PHILIPPINES ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 317 PHILIPPINES ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 318 PHILIPPINES ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 319 PHILIPPINES POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 320 PHILIPPINES POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 321 PHILIPPINES POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 322 PHILIPPINES POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 323 PHILIPPINES POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 324 PHILIPPINES HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 325 PHILIPPINES POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 326 VIETNAM POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 327 VIETNAM POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)
TABLE 328 VIETNAM DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 329 VIETNAM DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 330 VIETNAM DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 331 VIETNAM ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 332 VIETNAM IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 333 VIETNAM BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 334 VIETNAM BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 335 VIETNAM BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 336 VIETNAM DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 337 VIETNAM DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)
TABLE 338 VIETNAM CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 339 VIETNAM ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)
TABLE 340 VIETNAM ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)
TABLE 341 VIETNAM ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)
TABLE 342 VIETNAM ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)
TABLE 343 VIETNAM POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)
TABLE 344 VIETNAM POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)
TABLE 345 VIETNAM POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)
TABLE 346 VIETNAM POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)
TABLE 347 VIETNAM POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 348 VIETNAM HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 349 VIETNAM POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 350 REST OF ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
图片列表
FIGURE 1 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: END USER COVERAGE GRID
FIGURE 8 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: SEGMENTATION
FIGURE 11 TEN SEGMENTS COMPRISE THE ASIA-PACIFIC POINT-OF-CARE DRUG ABUSE TESTING MARKET, BY DRUG TYPE
FIGURE 12 EXECUTIVE SUMMARY
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 RISING INCIDENCE OF DRUG ABUSE IS DRIVING THE GROWTH OF THE ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET FROM 2024 TO 2031
FIGURE 15 THE AMPHETAMINES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOB POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET IN 2024 AND 2031
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET
FIGURE 17 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DRUG TYPE, 2023
FIGURE 18 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DRUG TYPE, 2024-2031 (USD THOUSAND)
FIGURE 19 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DRUG TYPE, CAGR (2024-2031)
FIGURE 20 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 21 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRODUCTS 2023
FIGURE 22 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRODUCTS, 2024-2031 (USD THOUSAND)
FIGURE 23 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRODUCTS, CAGR (2024-2031)
FIGURE 24 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRODUCTS, LIFELINE CURVE
FIGURE 25 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRESCRIPTION, 2023
FIGURE 26 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRESCRIPTION, 2024-2031 (USD THOUSAND)
FIGURE 27 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRESCRIPTION, CAGR (2024-2031)
FIGURE 28 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRESCRIPTION, LIFELINE CURVE
FIGURE 29 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY SAMPLE TYPE, 2023
FIGURE 30 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY SAMPLE TYPE, 2024-2031 (USD THOUSAND)
FIGURE 31 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY SAMPLE TYPE, CAGR (2024-2031)
FIGURE 32 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY SAMPLE TYPE, LIFELINE CURVE
FIGURE 33 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY TESTING TYPE, 2023
FIGURE 34 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY TESTING TYPE, 2024-2031 (USD THOUSAND)
FIGURE 35 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY TESTING TYPE, CAGR (2024-2031)
FIGURE 36 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY TESTING TYPE, LIFELINE CURVE
FIGURE 37 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY APPLICATION, 2023
FIGURE 38 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY APPLICATION, 2024-2031 (USD THOUSAND)
FIGURE 39 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY APPLICATION, CAGR (2024-2031)
FIGURE 40 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 41 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY END USER, 2023
FIGURE 42 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY END USER, 2024-2031 (USD THOUSAND)
FIGURE 43 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY END USER, CAGR (2024-2031)
FIGURE 44 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY END USER, LIFELINE CURVE
FIGURE 45 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 46 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND)
FIGURE 47 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 48 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 49 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: SNAPSHOT (2023)
FIGURE 50 ASIA-PACIFIC POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: COMPANY SHARE 2023 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
